NRG-GY032

Open to Accrual

Return to Protocol Table

A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)

Principal Investigator

Matthew Powell, MD

Status

Open to Accrual

Date Opened To Accrual

April 16 2024

Disease Site

Gynecologic [GY]

Uterine Corpus

Phase

Developmental Therapeutics

Primary Objective

Estimate the rate of pelvic recurrence at 3 years in patients who are treated with a de-escalated adjuvant treatment directed by tumour molecular status.

Patient Population

Patients with POLE-mutated or p53wt/NSMP early-stage endometrial cancer (EC).

Target Accrual

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.